Attached files
| file | filename |
|---|---|
| 8-K - MICROMET, INC. | v202116_8k.htm |
| EX-5.1 - MICROMET, INC. | v202116_ex5-1.htm |
| EX-1.1 - MICROMET, INC. | v202116_ex1-1.htm |
Micromet
Announces Pricing of Public Offering of
9.9
Million Shares of Common Stock
Bethesda,
Maryland, November 11, 2010 – Micromet, Inc. (NASDAQ: MITI) announced today the
pricing of an underwritten public offering of 9,900,000 shares of its common
stock at a public offering price of $7.30 per share. The Company has
granted the underwriter a 30-day option to purchase an additional 1,485,000
shares of common stock from the Company to cover over-allotments, if
any. The closing of the offering is expected to take place on or
about November 16, 2010, subject to the satisfaction of customary closing
conditions.
The
Company plans to use the net proceeds from the financing primarily for general
corporate purposes, which may include research and development, capital
expenditures, working capital and general and administrative
expenses.
The
shares will be offered and sold pursuant to a shelf registration statement filed
with the Securities and Exchange Commission on October 16, 2009 and declared
effective on November 2, 2009 and a registration statement filed with the
Securities and Exchange Commission pursuant to Rule 462(b) promulgated under the
Securities Act of 1933, as amended. A prospectus supplement relating to the
offering will be filed with the Securities and Exchange Commission.
Piper
Jaffray acted as the sole underwriter for this offering. The
offering of these securities will be made only by means of a prospectus and
related prospectus supplement, copies of which may be obtained from Piper
Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402,
Telephone 1-800-747-3924.
This
press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy the Company's common stock, nor shall there be
any sale of the common stock in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any state or
jurisdiction.
About
Micromet
Micromet,
Inc. is a biopharmaceutical company focused on the discovery, development and
commercialization of innovative antibody-based therapies for the treatment of
cancer. Its product development pipeline includes novel antibodies generated
with its proprietary BiTE® technology, as well as conventional monoclonal
antibodies. The Company’s lead product candidate blinatumomab (MT103) is
currently the subject of a European pivotal trial in patients with minimal
residual disease positive acute lymphoblastic leukemia. Micromet has
collaborations with a number of leading pharmaceutical and biotechnology
companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune,
Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at
www.micromet.com
Safe
Harbor Statement
This
press release contains forward looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and other federal securities
laws. Any statements contained herein which do not describe historical facts,
including but not limited to, statements regarding the completion and timing of
the offering of our securities, are forward-looking statements that involve
risks and uncertainties that could cause actual results to differ materially
from those discussed in such forward-looking statements. Such risks and
uncertainties include uncertainties regarding the market conditions and investor
interest in the offering and other risks identified in our Securities and
Exchange Commission filings, including our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2010. We caution you not to place undue reliance on
any forward-looking statements, which speak only as of the date they are made.
We disclaim any obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or circumstances on
which any such statements may be based, or that may affect the likelihood that
actual results will differ from those set forth in the forward-looking
statements.
Contact:
Jennifer
Neiman
Director,
Corporate Communications
Micromet,
Inc.
240-235-0246
Jennifer.neiman@micromet.com